Janssen

Janssen launches iSTEP, a mobile medication and data management tech platform

Tuesday, October 17, 2017

Janssen Research & Development has established the Integrated Smart Trial & Engagement Platform (iSTEP), an information technology toolset developed to automate investigational product supply and data management in clinical trials. The approach, developed by Janssen, is available for industry-use and is designed to replace the paper-based conventional processes of managing clinical supplies and tracking patient health data with a cohesive suite of digital technologies.

[Read More]

NIH partners with 11 biopharmaceutical companies on cancer immunotherapy strategies

Friday, October 13, 2017

The NIH and 11 biopharmaceutical companies launched the Partnership for Accelerating Cancer Therapies (PACT), a five-year public-private research collaboration totaling $215 million as part of the Cancer Moonshot. PACT will initially focus on efforts to identify, develop and validate robust biomarkers—standardized biological markers of disease and treatment response—to advance new immunotherapy treatments that harness the immune system to attack cancer. The partnership will be managed by the Foundation for the National Institutes of Health (FNIH), with the Food and Drug Administration serving in an advisory role. 

[Read More]

Improved perception of the industry

Monday, June 12, 2017

The 2017 Global Pharmaceutical Reptrak study, prepared each year by Boston’s Reputation Institute, showed that the public’s perception of the pharmaceutical industry has improved, earning an industry score of 71.8, up from 68.2 in 2016. Furthermore, about 44% of respondents viewed the industry as having an excellent reputation, a seven point increase since 2016. Similarly, the number of respondents who perceived the industry as weak or poor declined, moving to 26% from 35% in 2016.

[Read More]

Resolving the conflict between feasibility and relevance

Monday, May 15, 2017

Multi-disciplinary teams tasked with the design of phase III clinical trials face a series of challenges. These include: determining the number of subjects required for statistically meaningful results, the time to complete the trial, budget and regulatory hurdles and guideline implications of the trial design.

[Read More]

Castleman Disease Collaborative Network, Janssen partner on study

Wednesday, April 12, 2017

The Castleman Disease Collaborative Network (CDCN), a global nonprofit organization dedicated to accelerating research and treatments for Castleman disease (CD), a rare immunological disease, announced a collaboration with Janssen Research & Development to conduct a proteomics study of idiopathic multicentric Castleman disease (iMCD), a deadly subtype of CD. This collaborative study has the potential to improve diagnosis and treatment for iMCD patients. The collaboration combines CDCN’s strong expertise in iMCD research and its world-wide network of physician researchers with Janssen’s industry leading iMCD research resources.

[Read More]

Janssen Pharmaceutical, Premier collaborate on atrial fibrillation study

Wednesday, April 5, 2017

Janssen Pharmaceuticals is collaborating with Premier on the first and largest study of its kind to address an unmet medical need for hospitalized patients with atrial fibrillation (AF) who are at risk for ischemic stroke. Named QUANTUM AF (Quantify Use of ANTicoagUlation to improve Management of AF), the study will evaluate the effect of a structured hospital quality improvement (QI) program on oral anticoagulant (OAC) use in these patients.

[Read More]